Supernus Pharmaceuticals reports a Q2 per-share loss of $1.01 on revenue of $219.06M, exceeding estimates by $13.63M.
Supernus Pharmaceuticals reported a second-quarter loss of $1.01 per share, contrasting with the $0.51 consensus estimate. The company noted the figures may not be directly comparable due to accounting adjustments or one-time items.
Revenue reached $219.06 million, up 32.4% year-over-year and $13.63 million above expectations. Growth was driven by four key products, which generated combined revenues of $175.7 million in the quarter.
The results reflect strong demand for the company’s portfolio, though the per-share loss highlights ongoing cost pressures or investment phases.